Tom 9, Nr 3 (2018)
WYBRANE PROBLEMY KLINICZNE
Opublikowany online: 2018-11-27
Wyświetlenia strony
436
Wyświetlenia/pobrania artykułu
588
Galectin-3: a potential biomarker for diagnostics of heart failure
Forum Zaburzeń Metabolicznych 2018;9(3):126-131.
Streszczenie
Heart failure is a dysfunction with varied ethology; one of possible causes is anticancer treatment with anthracyclines. Rapid diagnosis is important because the disease is associated with high mortality and morbidity. The only biomarkers fully approved for diagnostics of heart failure are natriuretic peptides. They are secreted by ventricular muscle cells in response to volume and pressure overload. However, their concentration can be influenced by other factors, such as age or gender. A potential marker, not affected by these issues might be galectin-3. Current studies showed that galectin can play particularly significant role in myocardial fibrosis and inflammation. Elevated galectin-3 concentration has been observed in such cardiovascular diseases as heart failure, atherosclerosis, stroke and myocardial infarction. The review summarizes results of studies which indicate the role of galectin-3 in inducing fibrosis and cardiac remodelling (processes which influence disease progression and prognosis) and showed its potential diagnostic value.
Słowa kluczowe: galectin-3heart failurebiomarkerscardiologyoncology
Referencje
- Wdowiak K, Spychałowicz W, Fajkis M, et al. Galectins in hematological malignancies – role, functions and potential therapeutic targets. Postępy Higieny i Medycyny Doświadczalnej. 2016; 70: 95–103.
- Kałan M, Witczak A, Mosiewicz J, et al. Rola galektyny-3 w niewydolności serca. Postepy Hig Med Dosw. 2015; 69: 1107–1113.
- Li LC, Gao J, Li J, et al. Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther. 2014; 351(2): 336–343.
- Eliaz I. The Role of Galectin-3 as a Marker of Cancer and Inflammation in a Stage IV Ovarian Cancer Patient with Underlying Pro-Inflammatory Comorbidities. Case Rep Oncol. 2013; 6(2): 343–349.
- Sygitowicz G, Tomaniak M, Filipiak KJ, et al. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience. Adv Clin Exp Med. 2016; 25(4): 617–623.
- Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members, Document Reviewers, ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
- Lok DJA, Van Der Meer P, de la Porte PWA, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010; 99(5): 323–328.
- Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010; 12(8): 826–832.
- Kramer F. Galectin-3: clinical utility and prognostic value in patients with heart failure. Research Reports in Clinical Cardiology. 2013: 13–22.
- Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004; 110(19): 3121–3128.
- van Kimmenade RR, Januzzi JL, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006; 48(6): 1217–1224.
- de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 2012; 272(1): 55–64.
- Anand IS, Rector TS, Kuskowski M, et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail. 2013; 15(5): 511–518.
- Gullestad L, Ueland T, Kjekshus J, et al. CORONA Study Group. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012; 33(18): 2290–2296.
- Lopez-Andrès N, Rossignol P, Iraqi W, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail. 2012; 14(1): 74–81.
- Felker GM, Fiuzat M, Shaw LK, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail. 2012; 5(1): 72–78.
- de Boer RA, Daniels LB, Maisel AS, et al. State of the Art: Newer biomarkers in heart failure. Eur J Heart Fail. 2015; 17(6): 559–569.
- Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem. 2012; 58(1): 267–273.
- Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012; 60(14): 1249–1256.
- Daniels LB, Clopton P, Laughlin GA, et al. Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study. Am Heart J. 2014; 167(5): 674–682.
- Bielecka-Dabrowa A, Gluba-Brzózka A, Michalska-Kasiczak M, et al. The multi-biomarker approach for heart failure in patients with hypertension. Int J Mol Sci. 2015; 16(5): 10715–10733.
- Imran TF, Shin HJ, Mathenge N, et al. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population. Am J Cardiol. 2017; 119(1): 57–64.
- Miró Ò, González de la Presa B, Herrero-Puente P, et al. The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure. Biomarkers. 2017; 22(8): 731–739.
- Yancy C, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2013; 62(16): 147–239.
- Moon BK, Lee YJ, Battle P, et al. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am J Pathol. 2001; 159(3): 1055–1060.
- Zhang H, Luo M, Liang Xi, et al. Galectin-3 as a marker and potential therapeutic target in breast cancer. PLoS One. 2014; 9(9): e103482.
- Koo JaS, Jung W. Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med J. 2011; 52(1): 89–97.
- Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014; 63(8): 809–816.
- Putt M, Hahn VS, Januzzi JL, et al. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. Clin Chem. 2015; 61(9): 1164–1172.
- van Boxtel W, Bulten BF, Mavinkurve-Groothuis AMC, et al. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. Biomarkers. 2015; 20(2): 143–148.
- de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009; 11(9): 811–817.
- de Boer RA, Edelmann F, Cohen-Solal A, et al. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail. 2013; 15(10): 1095–1101.
